Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular mechanisms of unique therapeutic potential of CUDC-907 for MEF2D fusion-driven BCP-ALL

22 Jul 2025

Abstract excerpt

Abstract MEF2D fusions are found in a special subtype of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with poor prognosis. In this study, we conducted high-throughput drug screenings using cell line and ex vivo cell model harboring, respectively, MEF2D::HNRNPUL1(MH) and MEF2D::BCL9(MB), the two major MEF2D fusions. We identified CUDC-907 as a highly potent dual-target inhibitor of PI3K/HDAC,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to CAR-T cell therapy research
Share to Chronic Myeloid Leukemia Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40695793
DOI: 10.1038/s41392-025-02310-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular mechanisms of unique therapeutic potential of CUDC-907 for MEF2D fusion-driven BCP-ALLPMID 40695793Read ↗

Clinical and molecular characteristics of MEF2D fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in MEF2D-HNRNPH1 gene fusionSemantic proximity Read ↗

<i>MEF2D</i> - <i>BCL9</i> Fusion Gene Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in AdolescentsSemantic proximity Read ↗

Functional, structural, and molecular characterizations of the leukemogenic driver MEF2D-HNRNPUL1 fusionSemantic proximity Read ↗

Dual Targeting of PI3K and HDAC by CUDC-907 Inhibits Pediatric Neuroblastoma GrowthSemantic proximity Read ↗

BRD4 PROTAC Degrader ARV-825 Inhibits T-Cell Acute Lymphoblastic Leukemia by Targeting 'Undruggable' Myc-pathway GenesSemantic proximity Read ↗

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial.Semantic proximity Read ↗

CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphomaSemantic proximity Read ↗

The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemiaSemantic proximity Read ↗

PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120Semantic proximity Read ↗

Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemiaSemantic proximity Read ↗

Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemiaSemantic proximity Read ↗

Direct targeted therapy for MLL‐fusion‐driven high‐risk acute leukaemiasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.